TICKERNERD
Menu
BCRXBCRXHealthcare · Drug Manufacturers - Specialty & Generic

BCRX Stock Forecast: BioCryst Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$9.56
−1.04% on the day

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. hold a median 12-month price target of $17 — +77.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 21 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.5B
Ticker Nerd rank
87 / 100
Median analyst target
$17
Analysts covering
11
Total return, dividends reinvested
1W
−1.8%
1M
+1.5%
YTD
+22.6%
1Y
+14.1%
From 52W high
−14.0%
From 52W low
+53.2%
$6
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

BCRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores BioCryst Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
87 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
95
Volatility
95
Accruals
91
Quality
81
Revisions
77
Growth
74
Momentum
50
Size
34
Issuance
10

Value (95): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (10): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BCRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BCRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26BCRXHigh $32Median $17Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says11 analysts
10 Buy1 Hold0 Sell
Low $12Median $17High $32

The green dot is the last close — the median target sits +77.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
6 Aug 2026RBC CapitalMaintainsOutperform$14 → $13
6 Aug 2026WedbushMaintainsOutperform$21 → $20
13 July 2026JP MorganReinstatesNeutral$12
7 July 2026RBC CapitalMaintainsOutperform$13 → $14
7 July 2026RBC CapitalMaintainsOutperform—
30 June 2026Cantor FitzgeraldMaintainsOverweight—
30 June 2026HC Wainwright & Co.MaintainsBuy—
7 May 2026CitizensMaintainsMarket Outperform—
7 May 2026WedbushMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
30 Jan 2026RBC CapitalMaintainsOutperform—
15 Dec 2025HC Wainwright & Co.MaintainsBuy—
5 Nov 2025CitizensMaintainsMarket Outperform—
4 Nov 2025BarclaysMaintainsEqual-Weight—
4 Nov 2025NeedhamMaintainsBuy—
15 Oct 2025Cantor FitzgeraldMaintainsOverweight—
15 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
15 Oct 2025NeedhamMaintainsBuy—
15 Oct 2025TD CowenReinstatesBuy$30
4 Aug 2025NeedhamMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BCRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BCRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+33.0%
Analysts raising
1
Analysts cutting
0
Fundamentals

BioCryst Pharmaceuticals, Inc. (BCRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
7.0×

Cheaper than 64% of US stocks

Price / sales
2.6×

Cheaper than 46% of US stocks

Price / book
−5.4×

Cheaper than 97% of US stocks

EV / EBITDA
6.8×

Cheaper than 49% of US stocks

Growth & margins
Revenue growth (YoY)
33.6%

Higher than 80% of US stocks

Earnings growth (YoY)
1441.7%

Higher than 98% of US stocks

Gross margin
98.2%

Higher than 99% of US stocks

Operating margin
45.1%

Higher than 94% of US stocks

Net margin
−40.9%

Higher than 11% of US stocks

Returns & dividend
Return on equity
−221.4%

Higher than 6% of US stocks

Return on assets
52.9%

Higher than 99% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

BCRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
BCRXBioCryst Pharmaceuticals, Inc.$2.5B
87
BHCBausch Health Cos., Inc.$2.4B
96
PBHPrestige Consumer Healthcare, Inc.$2.5B
59
RGCRegencell Bioscience Holdings Ltd.$2.6B
4
TRLVTrulieve Cannabis Corp.$2.1B
87
SUPNSupernus Pharmaceuticals, Inc.$2.6B
84
PRGOPerrigo Co. Plc$2.0B
69

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own BioCryst Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BCRX news & analysis

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research reported that the consensus price target suggests a 98.7% upside potential for BioCryst (BCRX). The article notes that while such price targets are often unreliable, an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Why it matters — BCRX watchers would care because the article highlights positive earnings estimate revisions as a potential signal of near-term stock movement, even though the price target itself may not be dependable.

Implied Volatility Surging for BioCryst Pharmaceuticals Stock Options

Zacks Investment Research · 11 Aug 2026neutral

A Zacks Investment Research report highlights that implied volatility is surging for BioCryst Pharmaceuticals (BCRX) stock options, drawing attention to recent movements in the options market.

Why it matters — BCRX watchers would care because elevated implied volatility in options can signal increased uncertainty or shifting expectations around the stock's future price direction.

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

24/7 Wall Street · 11 Aug 2026positive

The news item discusses BioCryst Pharmaceuticals as a potential acquisition target, noting it closed at $9.84 on August 10, 2026, which corresponds to a market capitalization of roughly $2.5 billion for the Durham-based rare-disease specialist.

Why it matters — BCRX watchers would care because the piece frames the company as an attractive, profitable rare-disease acquisition candidate, highlighting its current valuation.

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

BioCryst Pharmaceuticals held its Q2 2026 earnings call, discussing the company's financial and operational results for the quarter.

Why it matters — An earnings call transcript provides BCRX investors with management's perspective on the company's recent performance and outlook.

BioCryst Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

BioCryst Pharmaceuticals reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema.

Why it matters — For a BCRX watcher, the quarter shows commercial progress with ORLADEYO alongside advancement of the pediatric formulation and the navenibart pipeline program.

FAQ

Frequently asked questions about BCRX stock

What is the BCRX stock price forecast for 2026-2027?

The 11 Wall Street analysts covering BioCryst Pharmaceuticals, Inc. have a median 12-month price target of $17, with estimates ranging from $12 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is BCRX stock a buy right now?

Of the 11 analysts covering BioCryst Pharmaceuticals, Inc., 10 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioCryst Pharmaceuticals, Inc. 87 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BCRX?

As at 21 Aug 2026, BioCryst Pharmaceuticals, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (95 of 100).

Will BCRX stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +77.8% from the last close, and Ticker Nerd's factor model ranks BioCryst Pharmaceuticals, Inc. 87 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the BCRX stock forecast for 2030?

No analyst covering BioCryst Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BCRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $32 over the next 12 months.

How has BCRX stock performed over the past year?

BioCryst Pharmaceuticals, Inc. returned +14.1% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does BioCryst Pharmaceuticals, Inc. do?

BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases.

What is the latest news on BCRX?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?". Zacks Investment Research reported that the consensus price target suggests a 98.7% upside potential for BioCryst (BCRX). The article notes that while such price targets are often unreliable, an upward trend in earnings estimate revisions could indicate near-term upside for the stock.

Company

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Inc. is a biotechnology company specializing in the research, development, and commercialization of novel small-molecule drugs that target key enzymes in infectious and inflammatory diseases. Leveraging expertise in biology, computer modeling, and medicinal chemistry, the company focuses on structure-guided drug design to create oral therapeutics for difficult-to-treat rare diseases. Its pipeline and products address critical therapeutic areas, including hereditary angioedema, acute and uncomplicated seasonal influenza, filoviruses such as Ebola and Marburg viruses, and oncology. BioCryst Pharmaceuticals Inc. operates within the healthcare sector, particularly in drug manufacturing for specialty and generic applications, contributing to treatments for rare conditions and emerging infectious threats. Founded in 1986 and headquartered in Durham, North Carolina, it plays a vital role in advancing innovative therapies for underserved patient populations in the biopharmaceutical market.

CEO Mr. Charles K. Gayer · 435 employees · United States · https://www.biocryst.com